Platelet integrin αIIbβ3
Clearance mechanisms of von Willebrand factor and factor VIII
von Willebrand factor A1 domain
Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibα
Testing for heparin-induced thrombocytopenia
Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia
Inhibitors, what is the risk of treatment intensity?
Treatment characteristics and the risk of inhibitor development
Endothelial protein C receptor
Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia
Is tissue factor the ‘original sin’ of clotting, or is it factor VII?
Tissue factor around dermal vessels has bound factor VII in the absence of injury
Preserving vascular prostacyclin levels by microsomal prostaglandin E2 synthase isoform 1 inhibition
Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E2 biosynthesis in vascular smooth muscle cells
von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations
Autoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosis
ABO blood group, other risk factors and incidence of venous thromboembolism
Leptin induces tissue factor expression in human peripheral blood mononuclear cells
Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A
Protein C inhibitor directly and potently inhibits activated hepatocyte growth factor activator
Essential thrombin residues for inhibition by protein C inhibitor with the cofactors heparin and thrombomodulin
Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor
Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice
Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients
The critical role of myosin IIA in platelet internal contraction
Controlled shedding of platelet glycoprotein (GP)VI and GPIb–IX–V by ADAM family metalloproteinases
Platelets express three different splice variants of ApoER2 that are all involved in signaling
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy
Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis
Mechanical prophylaxis for travellers' thrombosis
A proposed structural model of human protein Z
High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes1
What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population
Acute respiratory tract infections in elderly patients increase systemic levels of hemostatic proteins